Additional file 4: of p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Giordano, Federica; Vaira, Valentina; Cortinovis, Diego; Bonomo, Sara; Goedmakers, Joyce; Brena, Federica; Cialdella, Annamaria; Ianzano, Leonarda; Forno, Irene; Cerrito, Maria; Giovannoni, Roberto; Ferri, Gian; Tasciotti, Ennio; Vicent, Silve; Damarco, Francesco; Bosari, Silvano; Lavitrano, Marialuisa; Grassilli, Emanuela

doi:10.6084/m9.figshare.8280347.v1

13046_2019_1199_MOESM4_ESM.pdf (469.85 kB)

Additional file 4: of p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

journal contribution

posted on 2019-06-14, 05:00 authored by Federica Giordano, Valentina Vaira, Diego Cortinovis, Sara Bonomo, Joyce Goedmakers, Federica Brena, Annamaria Cialdella, Leonarda Ianzano, Irene Forno, Maria Cerrito, Roberto Giovannoni, Gian Ferri, Ennio Tasciotti, Silve Vicent, Francesco Damarco, Silvano Bosari, Marialuisa Lavitrano, Emanuela Grassilli

Figure S3. p65BTK expression in T cells. FACS-purified CD3 cell lysate was tested for p65BTK expression by BN49 antibody and for p77BTK expression using the anti-BTK (#611117, from Becton Dickinson. 100 pg of purified p77BTK (#B4312, Sigma-Aldrich) were also loaded as a positive control. (PDF 469 kb)

Funding

Ministero dell’Istruzione, dell’Università e della Ricerca

History

Usage metrics

Keywords

NSCLC Drug resistance p65BTK BTK inhibitors EGFR EGFR inhibitors Targeted therapy Chemotherapy

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 4: of p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Funding

Ministero dell’Istruzione, dell’Università e della Ricerca

History

Usage metrics

Categories

Keywords

Licence

Exports